GlassScriptPhysician profile
David L Moore
NPI 1346503349
$3,806.48
in general payments reported to CMS, 2019-2025
31 companies · $1,897 in 2025
The $1,897 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.78 · 2021: $81.42 · 2022: $469 · 2023: $562 · 2024: $781 · 2025: $1,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,190 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $681.20 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $438.44 | 2024-2025 | Fanapt |
| Lundbeck LLC | $379.53 | 2022-2025 | Rexulti |
| Pfizer INC. | $376.64 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $301.36 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $269.57 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $216.90 | 2022-2025 | Caplyta |
| Amgen INC. | $169.52 | 2020-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $122.96 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Exact Sciences Corporation | $98.30 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $90.89 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.58 | 2023-2025 | Xifaxan |
| Alkermes, INC. | $71.68 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Glaxosmithkline, LLC. | $62.34 | 2023-2025 | Trelegy Ellipta |
| Becton, Dickinson and Company | $50.00 | 2023 | Bd Safetyglide |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $43.99 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $35.54 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $35.38 | 2023 | Quviviq |
| Novo Nordisk INC | $32.82 | 2022-2024 | Wegovy |
| Lilly USA, LLC | $30.11 | 2022-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $24.84 | 2025 | Eohilia |
| Indivior INC. | $24.16 | 2024 | Sublocade |
| Alexion Pharmaceuticals, INC. | $23.80 | 2024 | Strensiq |
| Xeris Pharmaceuticals, INC. | $22.21 | 2025 | Keveyis |
| Sunovion Pharmaceuticals INC. | $21.18 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.60 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.09 | 2022 | |
| Sumitomo Pharma America, INC. | $17.22 | 2023 | Gemtesa |
| Hikma Pharmaceuticals USA | $17.01 | 2023 | Ryaltris, Mitigare |
| Mannkind Corporation | $15.50 | 2022 | |
| Esperion Therapeutics, INC. | $13.12 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.